Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

6082 ARTÍCULOS , VIENDO DEL 4951 AL 4965

C3 and C5 complement cascade activation in brain injury and disease: Molecular mechanisms, pathological roles, and therapeutic implications

Woodard GE.

Neurochem Int. 2026 Jun;196:106161. doi: 10.1016/j.neuint.2026.106161. Epub 2026 Apr 21.

Benzimidazole as a Versatile Scaffold for Developing Neurotherapeutics Against Neurodegenerative Diseases

Barnwal N, Dubey S, Tiwari P.

ChemMedChem. 2026 Apr 14;21(7):e202500869. doi: 10.1002/cmdc.202500869.

The central role of mitochondrial dysfunction in neurodegeneration: implications for therapy

Raafat MA, Al-Hasnaawei S, Mousa HM, Hanumanthayya M, Sahoo S, Prathiba S, Singh G, Sinha A.

Mol Cell Biochem. 2026 Apr 27. doi: 10.1007/s11010-026-05542-w. Online ahead of print.

[Electroconvulsive therapy in a patient with Huntington's disease and depression: a case-report]

van Meerbeeck S, Coppens V, van Diermen L, Madani Y, Schrijvers D.

Tijdschr Psychiatr. 2026;68(2):82-85.

Disentangling suicidal ideation from behaviour in Huntington's disease: A Scoping review of definitions, risk factors, and research gaps

Stone F, Gathii E, Stewart I.

Gen Hosp Psychiatry. 2026 Mar 18;100:93-101. doi: 10.1016/j.genhosppsych.2026.03.014. Online ahead of print.

Revisited case for intranasal neuropeptide Y based therapeutics: From preclinical to clinical

Sabban EL, Tanelian A.

Neuropeptides. 2026 Jun;117:102605. doi: 10.1016/j.npep.2026.102605. Epub 2026 Mar 5.

Decreased Physical Activity as an Early Digital Biomarker in Huntington's Disease: A One-Year Observational Study

Simón-Vicente L, Calvo S, Mariscal N, Muñoz-Siscart I, Diaz-Piñeiro D, Rivadeneyra J, Cubo E.

Brain Behav. 2026 Feb;16(2):e71149. doi: 10.1002/brb3.71149.

m6A RNA methylation in neural plasticity, brain aging, and neurodegenerative vulnerability

Zhou X, Yu P, Shen X.

Mol Brain. 2026 Mar 29;19(1):34. doi: 10.1186/s13041-026-01297-z.

Roles of MAPKs, Including Those Activated by BDNF/TrkB, and Their Contribution in Neurodegenerative Diseases

Numakawa T, Kajihara R.

Int J Mol Sci. 2026 Jan 19;27(2):984. doi: 10.3390/ijms27020984.

Cryptoxanthin as a multitarget neuroprotective agent: mechanistic and in silico perspectives

Sadhukhan A, Chauhan A, Kumar M, Singh TG, Mujwar S, Awasthi A.

J Pharm Pharmacol. 2026 Mar 5;78(3):rgag029. doi: 10.1093/jpp/rgag029.

Axonopathy: mechanisms and potential therapeutic targets for neurodegenerative diseases

Shen R, Sung K, Ding J, Wu C.

Transl Neurodegener. 2026 Mar 24;15(1):13. doi: 10.1186/s40035-026-00543-7.

c-Jun in neurodegeneration: A key transcriptional regulator with therapeutic implications

Khan FA, Khan H, Awan UA, Nurahmat M, Nabijan M, Abduwaki M, Dong J.

Mol Ther Nucleic Acids. 2026 Feb 26;37(2):102874. doi: 10.1016/j.omtn.2026.102874. eCollection 2026 Jun 16.

APP-C31 pathology as a target in neurodegenerative diseases

Yip KC, Ho WF, Liu Y, Dawe GS.

J Biomed Sci. 2026 Feb 4;33(1):15. doi: 10.1186/s12929-026-01216-3.

Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery

Li X, Li J, Sun Y, Yao T, Lu Y, Liu S, Li H, Shi Y, Chen L, Zhao Y, Jiang W, Li Z, Zhou Z, Wang B, Zhang S, Yu H, Lai Y, Lu Q, Li Y, Li H, Xu Z, Wang G, Zhu Z.

Adv Drug Deliv Rev. 2026 Jul;234:115876. doi: 10.1016/j.addr.2026.115876. Epub 2026 Apr 22.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias